FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3145332293> ?p ?o ?g. }

• W3145332293 endingPage "486" @default.
• W3145332293 startingPage "476" @default.
• W3145332293 abstract "Pirfenidone has been shown to slow disease progression in patients with idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive fibrotic interstitial lung diseases (ILDs)) other than IPF. In view of the pathomechanistic and clinical similarities between IPF and other progressive fibrotic ILDs, we aimed to assess the efficacy and safety of pirfenidone in patients with four non-IPF progressive fibrotic ILDs.We did a multicentre, double-blind, randomised, placebo-controlled, parallel phase 2b trial (RELIEF) in 17 centres with expertise in ILD in Germany. Eligible participants were patients aged 18-80 years with progressive fibrotic ILD due to four diagnoses: collagen or vascular diseases (ie, connective tissue disease-associated ILDs), fibrotic non-specific interstitial pneumonia, chronic hypersensitivity pneumonitis, or asbestos-induced lung fibrosis. Other eligibility criteria included a forced vital capacity (FVC) of 40-90% predicted, a diffusing capacity of the lung for carbon monoxide of 10-90% predicted, and an annual decline of FVC of at least 5% predicted despite conventional therapy, based on at least three measurements within 6-24 months before enrolment. Patients who had received any previous antifibrotic therapy were excluded. We randomly assigned patients (1:1) to either oral pirfenidone (267 mg three times per day in week 1, 534 mg three times per day in week 2, and 801 mg three times per day thereafter) or matched placebo, added to their ongoing medication. Randomisation was done centrally using permuted block randomisation with varying block sizes stratified by the four diagnostic groups. Patients, investigators, statisticians, monitors, and the study coordinator were masked to treatment assignment until database closure. The placebo-controlled study period was 48 weeks (including up-titration). The primary endpoint was absolute change in percentage of predicted FVC (FVC % predicted) from baseline to week 48 in the intention-to-treat population, with imputation of missing data by the smallest sum of squared differences and attribution of deceased patients to the lowest rank in a rank ANCOVA model. Additionally, we did linear mixed-model repeated measures slope analyses of FVC % predicted longitudinal data over the course of the study as a prespecified sensitivity analysis and post-hoc sensitivity analyses of the primary endpoint in the intention-to-treat population using imputation methods of last observation carried forward [LOCF] and a regression-based multiple imputation procedure. Safety was assessed in all patients who received at least one dose of study medication. This trial is registered with EudraCT 2014-000861-32; DRKS00009822 and is no longer recruiting.Between April 5, 2016, and Oct 4, 2018, we randomly assigned 127 patients to treatment: 64 to pirfenidone, 63 to placebo. After 127 patients had been randomised, the study was prematurely terminated on the basis of an interim analysis for futility triggered by slow recruitment. After 48 weeks and in the overall population of 127 patients, rank ANCOVA with diagnostic group included as a factor showed a significantly lower decline in FVC % predicted in the pirfenidone group compared with placebo (p=0·043); the result was similar when the model was stratified by diagnostic group (p=0·042). A significant treatment effect was also observed when applying the LOCF and multiple imputation methods to analyses of the primary endpoint. The median difference (Hodges-Lehmann estimate) between pirfenidone and placebo groups for the primary endpoint was 1·69 FVC % predicted (95% CI -0·65 to 4·03). In the linear mixed-model repeated measures slope analysis of FVC % predicted, the estimated difference between treatment and placebo groups from baseline to week 48 was 3·53 FVC % predicted (95% CI 0·21 to 6·86) with imputation of deaths as prespecified, or 2·79 FVC % predicted (95% CI 0·03 to 5·54) without imputation. One death (non-respiratory) occurred in the pirfenidone group (2%) and five deaths (three of which were respiratory) occurred in the placebo group (8%). The most frequent serious adverse events in both groups were infections and infestations (five [8%] in the pirfenidone group, ten [16%] in the placebo group); general disorders including disease worsening (two [3%] in the pirfenidone group, seven [11%] in the placebo group); and cardiac disorders (one ([2%] in the pirfenidone group, 5 [8%] in the placebo group). Adverse events (grade 3-4) of nausea (two patients on pirfenidone, two on placebo), dyspnoea (one patient on pirfenidone, one on placebo), and diarrhoea (one patient on pirfenidone) were also observed.In view of the premature study termination, results should be interpreted with care. Nevertheless, our data suggest that in patients with fibrotic ILDs other than IPF who deteriorate despite conventional therapy, adding pirfenidone to existing treatment might attenuate disease progression as measured by decline in FVC.German Center for Lung Research, Roche Pharma." @default.
• W3145332293 created "2021-04-13" @default.
• W3145332293 creator A5000115904 @default.
• W3145332293 creator A5000874456 @default.
• W3145332293 creator A5001094500 @default.
• W3145332293 creator A5002362593 @default.
• W3145332293 creator A5002418799 @default.
• W3145332293 creator A5003639441 @default.
• W3145332293 creator A5004169376 @default.
• W3145332293 creator A5004209671 @default.
• W3145332293 creator A5006969715 @default.
• W3145332293 creator A5007048597 @default.
• W3145332293 creator A5009660507 @default.
• W3145332293 creator A5009673855 @default.
• W3145332293 creator A5012574601 @default.
• W3145332293 creator A5013848299 @default.
• W3145332293 creator A5016212281 @default.
• W3145332293 creator A5016488176 @default.
• W3145332293 creator A5018414049 @default.
• W3145332293 creator A5020173096 @default.
• W3145332293 creator A5022776228 @default.
• W3145332293 creator A5023852052 @default.
• W3145332293 creator A5024585720 @default.
• W3145332293 creator A5024943477 @default.
• W3145332293 creator A5027241081 @default.
• W3145332293 creator A5027445532 @default.
• W3145332293 creator A5027887614 @default.
• W3145332293 creator A5028247097 @default.
• W3145332293 creator A5028265360 @default.
• W3145332293 creator A5029748189 @default.
• W3145332293 creator A5030169766 @default.
• W3145332293 creator A5030364116 @default.
• W3145332293 creator A5031259235 @default.
• W3145332293 creator A5031909066 @default.
• W3145332293 creator A5032014590 @default.
• W3145332293 creator A5033766167 @default.
• W3145332293 creator A5033796284 @default.
• W3145332293 creator A5034207468 @default.
• W3145332293 creator A5035492584 @default.
• W3145332293 creator A5038469924 @default.
• W3145332293 creator A5038615410 @default.
• W3145332293 creator A5039583899 @default.
• W3145332293 creator A5039750637 @default.
• W3145332293 creator A5041085608 @default.
• W3145332293 creator A5041868557 @default.
• W3145332293 creator A5047166105 @default.
• W3145332293 creator A5048551539 @default.
• W3145332293 creator A5049434757 @default.
• W3145332293 creator A5051641744 @default.
• W3145332293 creator A5053293174 @default.
• W3145332293 creator A5055038206 @default.
• W3145332293 creator A5055428229 @default.
• W3145332293 creator A5057577843 @default.
• W3145332293 creator A5058423075 @default.
• W3145332293 creator A5059136692 @default.
• W3145332293 creator A5059857876 @default.
• W3145332293 creator A5064642654 @default.
• W3145332293 creator A5064818419 @default.
• W3145332293 creator A5065240422 @default.
• W3145332293 creator A5065504836 @default.
• W3145332293 creator A5066080900 @default.
• W3145332293 creator A5067852431 @default.
• W3145332293 creator A5068767774 @default.
• W3145332293 creator A5069886120 @default.
• W3145332293 creator A5071628869 @default.
• W3145332293 creator A5071719242 @default.
• W3145332293 creator A5072492631 @default.
• W3145332293 creator A5073003316 @default.
• W3145332293 creator A5074397827 @default.
• W3145332293 creator A5076127908 @default.
• W3145332293 creator A5076229540 @default.
• W3145332293 creator A5078700584 @default.
• W3145332293 creator A5078911696 @default.
• W3145332293 creator A5078990370 @default.
• W3145332293 creator A5079122478 @default.
• W3145332293 creator A5079565649 @default.
• W3145332293 creator A5080637586 @default.
• W3145332293 creator A5081096300 @default.
• W3145332293 creator A5082092472 @default.
• W3145332293 creator A5082183908 @default.
• W3145332293 creator A5086416072 @default.
• W3145332293 creator A5090203143 @default.
• W3145332293 date "2021-05-01" @default.
• W3145332293 modified "2023-10-18" @default.
• W3145332293 title "Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial" @default.
• W3145332293 cites W2057292199 @default.
• W3145332293 cites W2059707463 @default.
• W3145332293 cites W2060393870 @default.
• W3145332293 cites W2104372974 @default.
• W3145332293 cites W2113186524 @default.
• W3145332293 cites W2138838035 @default.
• W3145332293 cites W2168666423 @default.
• W3145332293 cites W2260133387 @default.
• W3145332293 cites W2574998181 @default.
• W3145332293 cites W2752836823 @default.
• W3145332293 cites W2799479598 @default.
• W3145332293 cites W2945521814 @default.
• W3145332293 cites W2949902755 @default.

• next